VTE Prevention Market Trends in 2025 and Beyond

The global demand for VTE care is surging as hospitals invest in cutting-edge solutions like compression pumps and AlphaVac devices to manage blood clots non-invasively and effectively.

Meticulous Research^®�"a leading global market research company, published a research report titled, by Device (Thrombectomy, Inferior Vena Cava Filter [Retrievable, Permanent], Stockings, Compression Pump) Application (DVT, Pulmonary Embolism) End User (Hospital, Ambulatory Care Centre) �" Global Forecast to 2030.’ According to this latest publication from Meticulous Research^®, the venous thromboembolism treatment market seems to be on a steady rise. It is projected to reach $4.4 billion by 2030, growing at about 7.2% annually. The rise makes sense. With more cancer diagnoses, a growing number of orthopedic procedures, and chronic conditions like diabetes on the rise, VTE risks are naturally increasing. DVT is becoming more common, and that is driving demand for treatment. Hospitals are moving toward minimally invasive procedures, and the use of thrombectomy devices is growing. Access to VTE prevention methods and prophylaxis medications has also improved in many parts of the world. That said, it is not without issues. Product recalls, side effects from compression garments, and low public awareness are real barriers. But even with these problems, the overall outlook still seems strong.

Key Players

The key players profiled in the venous thromboembolism treatment market report are ALN Implants chirurgicaux (ALN Surgical Implants) (France), AngioDynamics, Inc. (U.S.), Argon Medical Devices, Inc. (U.S.), ArjoHuntleigh AB (Sweden), Boston Scientific Corporation (U.S.), Cardinal Health, Inc. (U.S.), Cook Group Incorporated (U.S.), Koninklijke Philips N.V. (Netherlands), DS MAREF Co., LTD (South Korea), Enovis Corporation (U.S.), LifeTech Scientific Corporation (China), Medtronic plc (Ireland), and Stryker Corporation (U.S.).

Minimally Invasive Clot Removal Gaining Ground in Vascular Care

The global venous thromboembolism treatment market is segmented by device (thrombectomy devices, inferior vena cava filters {retrievable filters and permanent filters}, stockings, compression pumps, and other devices & accessories), application (deep vein thrombosis and pulmonary embolism), end user (hospitals, ambulatory care centres, and other end users), and geography. The study also evaluates industry competitors and analyses the market at the global and regional levels. In 2023, thrombectomy devices led the way among all product types and will likely keep that lead going forward. These are the tools doctors use to pull out blood clots �" in cases like DVT, pulmonary embolism, strokes, and other forms of venous thromboembolism (VTE). There are a few reasons they are so widely used now. For one, heart and circulation problems are more common than ever. And let us be honest �" most patients (and doctors) prefer treatments that do not involve open surgery. That is why minimally invasive procedures are getting more popular. A good example is the AlphaVac system from AngioDynamics, which got cleared by the FDA back in 2021. It works without cutting open the body and can be used in different parts of the vascular system. That kind of flexibility is becoming a real advantage. Hospitals are also starting to spend more on this kind of tech, especially as awareness grows around the risks of VTE �" which can happen after surgery or in people with serious illnesses like cancer.

Rising DVT Cases Push Demand for Preventive Devices

In 2023, deep vein thrombosis showed up as the top application in the VTE treatment market. Honestly, that lines up with the way things are going. Older populations are growing, and lifestyle habits are not improving much. You have got more people staying inactive, eating poorly, and dealing with weight gain. All of that adds up to more DVT cases. Obesity, in particular, slows blood flow and leads to vein problems like venous stasis, which increases the chance of clot formation. According to WHO, back in 2021, over a billion people were classified as obese. That includes 650 million adults, 340 million teens, and nearly 40 million kids. That number’s not slowing down either �" it is expected to rise by another 167 million by 2025. Because of this, hospitals and clinics are paying more attention to DVT prevention. You see more use of devices, especially for folks recovering from surgeries or anyone who is stuck in bed for a long time. People are more aware now too, so early diagnosis is happening more often.

Hospitals Lead the Way in Venous Thromboembolism Treatment Market

Hospitals led the Venous Thromboembolism Treatment Market in 2023. That makes sense. A lot more people are being diagnosed with VTE and DVT now. Hospitals are usually where they go first. They have the tools like thrombectomy devices to remove clots and compression pumps for VTE prevention. These are not common in smaller clinics. Also, hospitals have the staff. Specialists, surgeons, technicians all in one place. People prefer that. It is easier when everything from diagnosis to surgery happens in the same building. Doctors are giving VTE prophylaxis medications after surgery or during long hospital stays. Patients and families are asking more questions too. So, with better equipment, higher budgets, and more trained professionals, hospitals stay at the front of VTE treatment.

Asia-Pacific Emerges as a Fast-Growing Market for VTE Care and Devices

The Venous Thromboembolism Treatment Market is growing differently in each part of the world. In 2022, North America had the biggest share. That is expected the U.S. and Canada have advanced healthcare, better access to VTE prevention tools, and more public awareness of DVT. Europe follows close behind, with strong use of prophylaxis medications and steady hospital investment in thrombectomy devices. But if you are looking at fast growth, it’s happening in Asia-Pacific. Countries like India, China, and Japan are seeing more patients with chronic conditions and sedentary lifestyles two major VTE risk factors. Healthcare spending is rising, and governments are working on improving early diagnosis. Other regions like Latin America and the Middle East & Africa are catching up slowly. Access is still a problem in some rural areas, but awareness is growing, and more hospitals are investing in VTE care equipment.

 Key Questions Answered in the Report:

 

What is the projected market size of the venous thromboembolism treatment market by 2030?

 

What is the estimated CAGR for the VTE treatment market during the forecast period?

 

Why are thrombectomy devices leading the VTE treatment device segment?

 

What is the role of compression pumps in preventing VTE?

 

Why is deep vein thrombosis (DVT) the leading application in the VTE treatment market?

 

How do lifestyle changes contribute to the rise in DVT cases?

 

Who are the major players in the global VTE treatment market?

 

How are companies like AngioDynamics and Medtronic innovating in this space?

 

What are the biggest unmet needs in the VTE treatment market today?

 

How is low public awareness affecting VTE diagnosis and treatment?

 

Contact Us:
Meticulous Research®
Contact Sales- [phone]
Connect with us on LinkedIn-